Background: Insulinoma is the commonest functioning pancreatic neuroendocrine tumor causing hyperinsulinemic hypoglycemia. Aim: This study is aimed to evaluate the clinical features, preoperative laboratory and imaging diagnosis and pathologic findings of insulinoma. Methods: Data of the patients from 2001 to 2016 diagnosed as insulinoma in Tongji Hospital, China were retrospectively extracted and analyzed. Results: A total of 40 patients were diagnosed as insulinoma with a male/female ratio of 0.68:1. The median onset age was 46.5 years. Nearly all the included patients presented neurological symptoms and 60% presented autonomic symptoms. More than 95% of the patients met the functional European Neuroendocrine Tumor Society criteria including glucose, insulin and C-peptide levels. The preoperative detection rates of ultrasonography, enhanced computed tomography, magnetic resonance imaging, and endoscopic ultrasonography were 60.50%, 84.95%, 80% and 83.3% respectively. The joint imaging examinations can markedly increase the detection rate. The mean tumor size was 1.89 6 0.72 cm. Ki-67 index by histopathological diagnosis were all less than 20%. The positive rates of insulin, synaptophysin and chromogranin A were close to 100%. Conclusion: Laboratory tests of glucose, insulin and C-peptide are reliable for preoperative diagnosis. Combination of the imaging examinations can improve the diagnosis.
Introduction
Pancreatic neuroendocrine tumors (PNETs) are neoplasms originating from pancreatic islet cells and can be further divided into functioning PNETs (F-PNETs) and non-functioning PNETs (NF-PNETs) based on whether the tumor cell secrets active substances. 1 Insulinoma belongs to F-PNETs, which is characterized by the special production of insulin with the consequence of endogenous hyperinsulinemic hypoglycemia. 2 Despite the low incidence of 1-3 per million per year, 3 insulinoma is the commonest F-PNET, accounting for 35%-40% of this group. 4 The major clinical presentations of insulinoma are grossly grouped into neurological symptoms (e.g. loss of consciousness, dizziness, fatigue, change in behavior and seizure) and autonomic symptoms including sweating, palpitation, hunger. 3 However, these symptoms are non-specific, resulting in missed diagnosis and delayed therapy. Regular functional diagnosis of insulinoma comprises glucose level, corresponding insulin and C-peptide levels according to most guidelines and consensus. 3, 5, 6 Other measurements, such as proinsulin, beta-hydroxybutyrate and amended insulinglucose ratio were also highlighted. [7] [8] [9] To localize the small tumor, trans-abdominal ultrasonography (US), computed tomography (CT)-scan enhancement, pancreas magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS) and SPECT/PET scan can be applied. 10 Although many reports conclude that EUS is the most sensitive method for preoperative diagnosis, [11] [12] [13] 
Materials and methods

Data sources and patient inclusion
This study was approved by the institutional ethic committee of the author's hospital. The patients' medical records from 2001 to 2016 in Tongji Hospital, Huazhong University of Science and Technology, Wuhan, PR China were reviewed. We collected the information if the patients (1) underwent surgery and were pathologically diagnosed with insulinoma; (2) presented recurrent hypoglycemic symptoms and documented blood glucose near or less than 3.0 mmol/L; and (3) had no other potential disorders which may cause hypoglycemia such as sulfonylurea intake, insulin injection, diabetes, hormone hypoglycemia, hepatic disease and dumpling syndrome.
Data extraction
The patients' general information (age, gender and duration of disease course), clinical presentations related to hypoglycemia, laboratory and imaging diagnostic data and pathological findings were recorded for further analysis.
Functional diagnostic tests included the lowest glucose level, corresponding insulin and C-peptide levels documented in medical records. The insulin to glucose ratio and C-peptide to glucose ratio were calculated. Imaging diagnosis referred to preoperative localization of the tumor. Trans-abdominal US, enhanced CT of the abdomen, MRI of pancreas and EUS were selectively performed in the included patients. The positive rates for single and joint examinations were calculated.
The tumor size was defined as the largest diameter (cm) of tumor recorded in surgery. The immune-histological staining biomarkers, including synaptophysin (Syn), chromogranin A (CgA), insulin, cytokeratin 8/18 (CK8/18), cluster of differentiation antigen 56 (CD56), pan-cytokeratin (PCK) and epithelial membrane antigen (EMA), were selectively accessed in the patients. The positive rate of each biomarker was calculated. The Ki-67 index was recorded for the grading of the tumors according to 2010 WHO classification.
14 Ki-67 index of 3% or less is considered as G1, of 3-20% is considered as G2 and of 20% or more is considered as G3.
Statistical analysis
Statistical analysis was performed using SPSS version 17.0 (SPSS Inc, Chicago, IL, USA). Continuous data were presented as median, range and/or standard deviation (SD). The rate or percentage was expressed as percentage.
Spearman's correlation analysis was used for the correlation analysis between parameters and statistical significance was set at P < 0.05. The clinical manifestations related to hypoglycemia were variable. Three autonomic symptoms and seven neurological symptoms were recorded according to the patients' narratives (Table 1) . Twenty four out of 40 patients complained autonomic hypoglycemic symptoms, including sweating, palpitation and hunger. Among, sweating due to hypoglycemia is the most common symptoms, occupying 55.0% of the total subjects. Nearly all included patients presented neurological symptoms and consciousness loss was the most frequently presented.
Results
General information and clinical features
Laboratory diagnostic results
The lowest plasma glucose level together with the corresponding insulin and C-peptide levels during hospitalization were recorded in Table 2 . The lowest plasma glucose level was 1.89 mmol/L on average, with a corresponding insulin level of 27.76 mU/L and C-peptide level of 4.58 mg/L. The ratio of insulin to glucose was 1.31 and C-peptide to glucose was 3.33. According to the recent European Neuroendocrine Tumor Society criteria for the diagnosis of insulinoma, 5 our data demonstrated 94.1% of these patients with a glucose level below 3.0 mmol/L. The insulin and C-peptide levels in all included patients reached the diagnostic range (Table 3) . These results emphasize the importance of insulin and C-peptide in insulinoma diagnosis.
Imaging diagnostic examinations
Each patient underwent one or more imaging examinations including trans-abdominal US, enhanced CT, MRI and EUS. Amongst, enhanced CT presented the highest positive rate for Table 4 . Joint imaging examination markedly increased the preoperative detection rate. Most of patients received CT evaluation together with US, with the positive detection rate of 96.9% (31/32). It is significant that the diagnostic rate was 100% when patient underwent CT plus MRI, CT plus EUS and US plus MRI (Table 4) . EUS combined with US failed to improve the detection rate, which presented the lowest rate (83.3%). Based on these results, we assume that joint imaging examination can be recommended before operation except the combination of EUS and trans-abdominal US.
Histopathological results
The tumor size was recorded as maximum diameter (Table 5) and the mean value was 1.89 6 0.72 cm (Range: 1.0-3.0 cm). The size of most tumors was between 1 cm and 2 cm, occupying 52.8% of the total. There was no tumor more than 3 cm identified in this institution. As shown in Table 6 , Spearman's correlation analysis showed a weak correlation between tumor size and I/G ratio (R ¼ 0.354, P ¼ 0.047). However, the stratification analysis failed to identify the significant association of tumor size with either imaging examinations or laboratory tests.
According to Ki-67 index (Table 5) , most of patients were belong to G1 phase (86.4%) according to WHO classification standard, indicating a well prognosis of the disease. Data on histopathological staining were analyzed as well. Insulin staining was performed in specimens from 23 patients. Only one specimen showed negative staining and the positive percentage was 97.0%. Syn, CgA and CK8/18 biomarkers were positive in all postoperative samples. Only six samples underwent epithelial membrane antigen EMA staining and no samples showed positive staining (Table 5) .
Discussion
In the present study, we summarized the clinical features, diagnosis and pathological results of 40 patients with insulinoma in our hospital during [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] [2016] . Largely in accordance with other previous studies, 15, 16 our data showed that insulinoma was a mid-age onset disease and tended to occur in female with a course of about 4 years before clear diagnosis. The tumor size of the included patients in our hospital was mostly between 1 and 2 cm, making it more difficult to be detected than NF-PNETs.
17,18
Both laboratory results and imaging examinations are essential for the diagnosis of insulinoma. Almost all the patients presented hyperinsulinemic hypoglycemia, which is important for functional diagnosis of insulinoma. 3 In our study, there were more than 95% patients who recorded lowest glucose and the corresponding insulin and C-peptide levels during hypoglycemic episode met the diagnostic criteria (Table 1) , indicating the insulin and C-peptide as reliable indicators for insulinoma diagnosis. Interestingly, our studies demonstrated that the tumor size was positively correlated to insulin/glucose ratio. The insignificant findings by stratification analysis may be partly attributed to the limited sample size, especially the subgroup with tumor size 1. Nevertheless, based on these data, it is assumed that it is the tumor with small size that contributes to higher insulin/glucose ratio. We further compared the accuracy of different imaging diagnostic methods. For the single imaging examination, abdominal US had the lowest accuracy of 60.5% although it is the most available imaging method. Accordingly, it is not suitable if only US is performed for insulinoma diagnosis. enhanced CT and EUS were the most sensitive methods compared with other approaches performed on the patients. Additionally, CT presented a weak advantage over EUS. These findings were not completely consistent with previous studies, which concluded the absolute superiority of EUS for preoperative diagnosis.
11-13
When patients underwent more than one imaging methods, the diagnostic accuracy was obviously improved with the lowest rate of 83.3% (US plus EUS). These results indicate that joint imaging examinations are recommended for diagnosis except the US plus EUS. However, only 10 patients underwent MRI examination. Thus, the accuracy of MRI plus CT or US needs further investigation. Insulinoma is exceedingly rare with the 5-year survival rate up to 56%. [19] [20] [21] According to the WHO grading standard based on Ki-67 index, tumor grade influences overall survival, with low-grade tumors (Ki-67 < 3%) suggesting a better outcome. 22, 23 Our study showed that most patients were in G1 phase, indicating a well prognosis. This result is accordant with the findings reported by Scarpa among Italian patients. 24 Additionally, Scarpa et al. reported that G2 and G3 neoplasms showed a respective 2-fold and 10-fold higher risk of death. They suggested the cut-off value of Ki-67 at 5 and 20% for prognostic categories. 24 However, our current study failed to collect the postoperative follow-up data for these included patients. It would be significant to explore the predictive value of Ki-67 index of insulinoma in Chinese subjects. CgA, Syn, CD8/18 and insulin are important for pathological diagnosis of insulinoma. CgA and Syn are glycoproteins found in many neuroendocrine cells including islet cell, both of which are common biomarkers for pNETs. [25] [26] [27] [28] [29] The staining for all the samples was positive, indicating the diagnostic value for these two biomarkers. Insulin is specifically expressed by b cells and regarded as a specific marker for insulinoma. 30 The positive percentage of insulin staining was 97.0% in our study, much higher than the result of 68.4% in another clinical study for Chinese subjects. 15 There was only one sample presenting negative staining, which may be attributed to the rapid release of insulin from the insulin-producing cells. 3 
Conclusions
In conclusion, our study suggests that insulin and C-peptide tests are reliable indicators for the diagnosis of insulinoma. CT and EUS were the most sensitive imaging methods compared with other approaches. Joint examinations are recommended except US plus EUS. CgA and Syn are two valuable biomarkers for pathological diagnosis. 
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